Baohe Pingwei power plus neoadjuvant chemotherapy for gastric cancer

Table 1 Comparison of baseline data between the control group and the observation group

Characteristic		Control group (n = 54)	Observation group (n = 26)	χ2/t	P value
Age (mean ± SD, years)		68.85 ± 1.26	68.33 ± 1.12	1.790	0.077
Gender	Male	41 (75.93)	22 (84.62)	0.792	0.374
	Female	13 (24.07)	4 (15.38)
Tumor location	Gastric antrum or pylorus	39 (72.22)	18 (69.23)	0.315	0.753
	Stomach body	8 (14.81)	3 (11.54)
	Gastric fundus or cardia	7 (12.97)	5 (19.23)
Clinical staging	Phase II	23 (42.59)	16 (61.54)	2.521	0.112
	Phase III	31 (57.41)	10 (38.46)
Surgical scope	Partial excision	25 (46.30)	17 (65.38)	2.564	0.109
	Fully cut	29 (53.70)	9 (24.62)
Tumor size	< 2 cm	8 (14.81)	7 (26.92)	0.672	0.502
	2-5 cm	36 (66.67)	14 (53.85)
	> 5 cm	10 (18.52)	5 (19.23)
Degree of differentiation	High	2 (3.70)	2 (7.69)	0.455	0.649
	In	16 (29.63)	8 (30.77)
	Low	36 (66.67)	16 (61.54)
Smoke	Have	23 (42.59)	10 (38.46)	0.124	0.725
	Without	31 (57.41)	16 (61.54)
Drink	Have	36 (66.67)	19 (73.08)	0.336	0.562
	Without	18 (33.33)	7 (26.92)
Hypertension	Have	22 (40.74)	14 (53.85)	1.218	0.270
	Without	32 (59.26)	12 (46.15)
Diabetes mellitus	Have	17 (31.48)	13 (50.00)	2.568	0.109
	Without	37 (68.52)	13 (50.00)

Data are presented as n (%). SD: Standard deviation